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Abstract 
In previously healthy persons suffering from acute illnesses, nosocomial infections are frequent. Their 
prevalence suggests the existence of as yet unknown conditions that may promote care-related 
infection. This study assessed whether 1) the measurement of plasma chromogranin A, a stress-related 
protein involved in innate defence, is related to nosocomial infection risk and 2) whether any 
chromogranin-A-derived fragment included in vasostatin-I displays immunosuppressive activities 
related to AP-1 or NF-kappa B down regulation. At the clinical level, trauma patients and healthy 
controls were recruited to beeligible. Clinical histories were recorded, and standard biological tests 
(including plasma chromogranin A) were performed. For 9 randomly chosen patients and 16 controls 
the time-dependent concentrations of chromogranin A was assessed twice a-day over 66 h. The data 
show that trauma patients present a higher value of chromogranin A concentration during 66h 
incomparison with healthy controls. In addition, patients maintaining this significant increase in CGA 
readily develop nosocomial infections. We therefore studied the effects of chromogranin A-derived 
peptides on monocytes, focusing on transcription factors which play a central role in inflammation. In 
vitro assay demonstrated that a chromogranin A-derived fragment (CGA47-70) displays a significant 
inhibition of NF-kappa B and AP-1 transcriptional activities in these cells. In conclusion, the 
occurrence of nosocomial infection in trauma patients is associated with significantly increased plasma 
chromogranin A concentrations. Down regulation of the two transcription factors by CGA 47-70 might 
induce early acquired immune defect after a serious medical stress. 
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Introduction 
Nosocomial infections (NI), also often called care-related infections, still pose a major problem as 
recently confirmed in a large investigation(1). Their prevalence is now around 5% in hospitalized 
patients, and up to 19% in critically ill patients. In the absence of either proper hygiene or immune 
suppressive drug administration, clinicians readily accept immune paralysis as a cause of their 
occurrence (2-4). NI are also thought to be associated with transient immune cellular defects(5)whose 
improvement is expected to ameliorate the outcome of the initial disease. The high prevalence of NI in 
previously healthy persons undergoing a major medical stress suggests the existence of multifactorial 
mechanisms able to trigger common innate immune defects that favour the occurrence of care-related 
infections. Multiple trauma provides an attractive model to study the time-dependent immune 
consequences of an acute and severe disease (early after its onset)for two reasons: 1) the exact 
beginning of the stress is usually defined; 2) trauma frequently occurs in healthy young persons, which 
excludes confounding factors such as associated diseases or treatments. As in other severe injuries, the 
immune response to multiple trauma includes not only a severe hyper inflammatory response called 
systemic immune inflammatory response syndrome (SIRS) but also immune paralysis often leading to 
NI (1-5).  
Taking into account that: 1) some transient innate defence dysfunction may be related to the innate 
immune system(6 ,7) and 2) severity of the shock could be a factor involved in the occurrence of NI, 
we focused our attention on chromogranin A in the plasma (pCGA)(8). CGA is a protein shown to 
connect the stress-activated adrenal medulla and immunity (9), and pCGA is a predictor of severity in 
critically ill patients (9). More recently, pCGA was evaluated after burn trauma showing that high 
concentration predicts organ dysfunction (10). CGA is enclosed in storage vesicles of chromaffin cells 
from the adrenal medulla and released with catecholamines upon splanchnic stimulation in vitro and in 
vivo(11). This acidic protein is also present in neutrophils(12) and under the action of proteases, it is 
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converted in numerous peptides with physiologically relevant functions (13, 14). VS-I (CGA1-76), the 
major natural CGA-derived peptide (13) has already been recognized as a biomarker of severity in 
acutely ill patients (15).  
In this study we postulated that CGA processing would play a role in driving some depression in 
monocytes’responses following trauma-related injury. We used both the clinical setting of trauma in 
humans and an in vitro model of NF-kappa B and AP-1 responses in genes up regulation in monocytes. 
Our data demonstrate a previously unidentified role of CGA in the occurrence of nosocomial infection 
through one of its derived peptide on immune cells. These finding support the notion that preventing 
the proteolysis of CGA may attenuate the immune depression following trauma. 
 
Materials and Methods 
1. CGA assessment in plasma from trauma patients 
This study was approved by our institutional review board for human experimentation. Over a period of 
one year, trauma victims requiring critical care were prospectively screened and included in this study 
if formal consent for participation could be obtained from the patient or next of kin. Exclusion criteria 
were: age under 18 and known reason for increased CGA release (i.e, steroid treatment, neuroendocrine 
tumor,…), independently of acute stress. Mortality was defined as death occurring before Day 28 after 
admission. Diagnosis of NI was based on classical criteria: the early-onset NI used in our study were 
infections detected after 48 h of hospital admission in patients without previous contact with healthcare 
services and not related with disease incubation that could have started before admission (16). 
Organ failure scores were assessed during the first days after admission (SAPS II, ISS, SOFA, delta 
Sofa max). Healthy controls were staff. 
Preparation of blood samples 
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Blood samples were collected as early as possible within 6 h of admission by vascular puncture into 
plasma-separator tubes (Becton Dickinson, France), immersed in ice or stored at 4°C until transported 
to the laboratory. Plasma was separated by centrifugation at 1500 g for 10 min at room temperature and 
stored in 200 µL aliquots at –20°C until analysis. In 9 randomly chosen patients, one tube was further 
collected every 12 h after the first sampling for 3 days to study the kinetic of the plasma CGA 
concentration. 
Laboratory assays 
The CGA assay is a sandwich ELISA (Cisbio Bioassays, France) with 2 monoclonal antibodies against 
human CGA amino acid sequences 145-197 and 198-245 (17). Procalcitonin concentration was 
measured on the Kryptor system (Brahms Diagnostic) according to the assay manufacturer’s 
recommendations; C-reactive protein was measured by immune turbidimetry, creatinine using an 
enzymatic method (Siemens ADVIA, Paris, France) and lactate in whole blood using a lactate 
oxydaseamperometric method (Roche, Cobas b221, Germany). 
 
2. In vitro studies on monocytes  
Cell culture 
The human monocytic THP-1 cell line (ATCC) was maintained at 37°C, under 5% CO2, in RPMI 
supplemented with 10% foetal calf serum and 2 mM L-glutamine. 
Preparation of synthetic rhodaminated peptides 
Rhodaminated synthetic peptides Rho-CGA47-70 and Rho-CGA7-40 were prepared on an Applied 
Biosystem 433A peptide synthesizer (Foster City, USA), using the stepwise solid-phase approach with 
9-fluorenylmethoxycarbonyl (Fmoc) chemistry. Thereafter, the synthetic peptides were purified by RP-
HPLC on a Macherey Nagel Nucleosil RP 300-7C18 column (10x250 mm; particle size 7 µm and pore 
size 100 nm). Rhodamine fluorophore 5(-)-carboxytetramethyl rhodamine was conjugated with 
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peptides at the N-terminal end as previously described (18). Synthetic peptides were analysed by mass 
spectrometry and automated Edman sequencing on an Applied Sequencing System (Applied 
Biosystems, Foster City, USA). Maldi-Tof mass measurements were carried out on an UltraflexTM 
TOF/TOF (Bruker Daltonics, USA). 
Florescence microscopy 
THP-1 cells were seeded at 1x106 cells/mL and treated with 20 µM of Rho-CGA47-70 or Rho-CGA7-40 
for 5 min or 15 min. Cells were then washed twice with cold PBS. Using a cytospincytocentrifuge 
(CytoSpin 4 Cytocentrifuge, Thermo Fisher), 2x105 cells were deposited onto a glass slide and fixed 
for 20 min at room temperature with 4% paraformaldehyde. Finally, coverslips were mounted onto the 
glass slides using Vectashield® Mounting Medium with DAPI (Vector Laboratories). Images were 
acquired using a fluorescence microscope (Nikon Eclipse TE200) at 60X magnification. 
Luciferase assays 
THP-1 were transiently transfected with a pNF-kappa B-Luc (a generous gift from Prof. Carine Van 
Lint, Université Libre de Bruxelles, Belgium) or pAP1-Luc reporter plasmids (Stratagene) using 
Lipofectamine™ LTX (Invitrogen). Twelve h post-transfection cells were treated with 20 µM of 
CGA47-66 for 1 h, 6 h or 24 h. Cells were then washed twice, lysed and luciferase activities were 
measured (Dual Luciferase® Reporter Assay System, Promega). The assay was normalized to total 
protein content (Bradford assay).The first control,with a relative luciferase activity of 1, corresponds to 
transfection by pNF-kappa B-Luc or pAP1-Luc reporter plasmids before treatment with peptide. 
Negative control corresponds to the treatment with CGA7-40. 
 
3. Statistics 
Variables were expressed as medians (interquartile range [25; 75]) or means +/- SD as indicated. 
Differences between continuous variables were tested using the Mann-Whitney test; differences 
between categorical variables were tested using Fisher’s exact test. Univariate analyses were performed 
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using a non-parametric analysis of variance by the Kruskal Wallis test, followed by Scheffé’s method 
analysis. When necessary, Anova for repeated non-parametric measures was used. Receiver-operating 
curves (ROCs) were constructed for biological biomarkers at the best cut-off level to predict NI 
occurrence, and the areas under the curve (AUC) were assessed and then compared using the Z statistic 
with correction for the correlation introduced by studying the same sample. The threshold of statistical 
significance was p<0.05.  
 
Results 
1. In vivo assessments 
Samples were obtained from 31 patients among 40 screened within 6 h from admission (Figure 1). 
Nine patients were excluded because (i) they chronically took proton pump inhibitors (n=4), (ii) no 
consent was obtained (n= 2) or (iii) they died within 2 days (n= 3). The baseline characteristics of the 
study population are presented in Table I. None of the patients had previous significant medical history. 
The patients suffered predominantly from blunt trauma (n= 28) due to motor vehicle accidents, a fall 
from a great height or gunshot (n=3). The length of stay in ICU ranged from 2 to 40 days (mean 13+/- 
11 days). The entirecohort required mechanical ventilation and circulatory support with 
norepinephrine. None needed renal support with haemodialysis over the first 3 days. Surgical 
intervention under general anaesthesia was required immediately after admission in 22/31 patients, and 
100% received blood transfusion in the first 24 h (mean transfusion requirement of 8 +/-15 units). Ten 
patients died within 28 days (mortality among study population 32%) either from intracranial 
hypertension (n=7) or from multiple organ failure subsequent to haemorrhagic shock (n=3). After Day 
2, 11/31 patients (35%) developed NI. Among these patients, 9 were randomly chosen for a 
longitudinal survey of pCGA concentration over 66 h after admission (Figure 2) and demographic and 
clinical characteristics (Table II). 
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Plasma release of CGA after trauma 
After the initial injury, the first concentration of CGA was significantly increased compared with 
healthy controls (112·3 [88·73; 144·3] ng/ml vs 19·5 [2·3; 36·6] ng/ml, p<0·0001) (Table I). As 
indicated in Figure 2, in a subset of 9 patients undergoing serial sampling, from its initial peak, the 
concentration of CGA showed a progressive decrease but remained significantly higher than the control 
values throughout the survey (p<0·001). 
Nosocomial infection occurrence according to plasma CGA concentration at admission 
Admission values of CGA were found to be significantly higher in those patients who developed NI 
(NI+) (111·1 [87·28; 149·0] ng/ml vs 63·08 [33·67; 204·7] ng/ml in patients without infections (NI-), 
p=0·003 (Figure 3). Using ROC curves, CGA concentration at admission predicted the occurrence of 
NI with a sensitivity of 100% and a specificity of 70% at the level of 67·25 ng/ml in the whole study 
population (n=31) (data not shown). AUC for this prediction was 0·837 (95% CI: 0·67-0·94), which 
was significantly greater than AUC for C reactive protein (0·557, 95% CI: 0·377-0·726, p=0·04) but no 
different from the AUC for procalcitonin (0·705, 95% CI: 0·524-0·848, p= 0·243). At the same CGA 
concentration, the positive likelihood ratio of the prediction was 3·33, whereas the negative likelihood 
ratio was zero.  
 
2. In vitro tests 
Vasostatin-I (VS-I; CGA1-76) (Figure 4) corresponds to the predominant natural CGA-derived fragment 
(13) and is highly conserved during evolution (12). In a previous study, we reported that significant 
amounts of VS-I are detected on admission in critically ill patients and that a plasma concentration 
above 3.97 ng/ml is associated with poor outcome (15). Since VS-I has never been reported as 
interacting with immune cells, we decided to test whether VS-I derived fragments have the ability to 
impact on inflammation. The first peptide we tested corresponds to CGA7-40, (Figure 4)which, as has 
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previously been reported, binds biological membranes with the disulfide bridge (19). The second 
peptide we tested is CGA47-70, including chromofungin (CGA47-66) which has already been described as 
a cell-penetrating peptide (18, 20) (Figure 4). 
This in vitro study includes 2 parts (1) the confocal microscopy of the interaction of the 2 rhodaminated 
peptides with THP1 cells and (2) the effects of CGA47-70 against NF-kappa B and AP-1 activities. 
Confocal microscopy 
We investigated the ability of Rho-CGA47-70 and Rho-CGA7-40 to penetrate the outer membrane of 
THP-1 cells, using a human monocytic cell line as a model. The cellular internalization was visualized 
via confocal microscopy after 5 min and 15 min of treatment. Figure 5A indicates that CGA47-70 was 
significantly internalized by cells, in line with its positive charges. The fluorescence was predominantly 
detected at 5 min and 15 min at the nuclear level. We note an increase of the nuclear fluorescence after 
15 min as compared with after 5 min (Figure 5A). Fluorescence was also detected at the perinuclear 
region with a lower level. In contrast, fluorescence of Rho-CGA7-40 could not be observed within cells-
(Figure 5B) showing a specific behaviour forRho-CGA47-70.  
CGA47-66inhibits the pro-inflammatory transcription factors NF-kappa B and AP-1 
We carried out luciferase assays and THP-1 cells were then transfected with the NF-kappa B-Luc or 
AP-1-Luc reporter construct and incubated with CGA47-70 for 1 h, 6 h and 24 h. Surprisingly, CGA47-66 
was able to inhibit both NF-kappa B and AP-1-mediated transcription in a time-dependent manner 
(Figure 6, columns 2–4 and columns 6-8, respectively). To be more precise, it was capable of inhibiting 
95% of NF-kappa B activity and 70% of AP-1 activity at 24 h post-treatment (Figure 6, column 4 and 
8, respectively). As NF-kappa B and AP-1 play a critical role in amplifying and perpetuating the 
inflammatory process by controlling the expression of numerous inflammatory genes (21), these results 
collectively reveal an anti-inflammatory potential for CGA47-66. 
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Discussion 
In our study population of multiple trauma patients, CGA levels were higher at admission and 
throughout the first 66 h after injury. Also, the plasma concentrations of CGA were significantly higher 
when care-related infection occurred. The stress induced by a life-threatening disease is thought to be 
responsible for the release of CGA within the plasma (9, for review); herein, the early damage control 
by surgery may also have partially contributed to such an increase (22). These data raise the question of 
a possible mechanism through which CGA and its endogenous fragments may contribute to a possible 
immunosuppression and the development of infection in trauma patients that are at risk of NI (4). 
Among the endogenous fragments, VS-I (CGA1-76) is predominantly produced and CGA47-66 is able to 
penetrate into immune cells (20). One recent report demonstrates that orally given VS-I protects mice 
against inflammatory colitis by reducing the cytokine-induced increase of permeability of intestinal 
epithelial cells and by promoting healing of injured cells (23). Production of CGA47-66 containing 
fragments may occur within the plasma or at cell surfaces by enzymes that are up regulated after a life-
challenging trigger. As a consequence of acute illness, several proteolytic enzymes are activated and 
up-regulated in a time-dependent manner in injured tissue and in circulating mononuclear cells when 
full-blown SIRS is occurring (24): peptidases, ADAMTS proteins and matrix metallo proteases(25-27). 
In addition some strains of Staphylococcus aureus release a glutamyl endopeptidase, able to break a 
bond after a glutamic residue and may therefore contribute to the production of several fragments such 
as CGA47-60 and CGA47-70 (18). Interestingly, numerous patients of ours developed care-related lung 
infection due to S. aureus, which may induce the production of CGA-derived fragments able to trigger 
or to increase an immune defect. 
To further characterize such an immune defect we report that CGA47-70, enters readily the monocytes, 
whereas its control peptide (CGA7-40) does not. CGA47-66 is a cell-penetrating peptide, as shown 
previously by our group (18, 20) and in vitro we showed that these cells exposed only to the CGA47-70 
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peptide display a rapid onset but long-lasting decrease of both NF-kappa B and AP-1 activities (Figure 
6). In contrast, another VS-I-derived peptide, (CGA7-40), was not able to modify the level of activity of 
these two transcriptional factors. These results suggest a subsequent down-regulation of their target 
genes (28), which are critical for the fine regulation of the balance between pro- and anti-inflammatory 
factors. In a recent paper it has also been reported that a cell-penetrating domain of human beta-
defensin 3 (hBD3-3) displays anti-inflammatory activity (29). Comparison of the sequences of CGA47-
70 andhBD3-3 is reported in Figure Supp. 1, Supplemental Digital Content 1, 
http://links.lww.com/SHK/A655. The authors demonstrated that hBD3-3 downregulated nuclear factor 
kappa B-dependent inflammation by suppressing the degradation of phosphorylated-I kappa B alpha 
and by down regulating active nuclear factor kappa B p65. As far as our peptide is concerned, CGA47-66 
has been shown to develop anti-calcineurin activities (20) resembling those of cyclosporin and FK 506 
(30), two immuno-suppressive drugs.  
Our study has limitations: 1) we have used a small and specific population (ie: multiple trauma 
patients) and 2) different stresses may induce CGA processing in relation with the previous medical 
history of patients.  
In conclusion, we speculate that in vivo the occurrence of nosocomial infections might be related with 
the VS-I processing into smaller fragments but the relevance of action of CGA47-66 needs further 
investigation of its role in vivo. These data support the need to rethink the concept of some forms of 
endogenous healthcare-associated infections: some of them may not be iatrogenic, but a consequence 
of immune deficiency due to severity of initial injury.  
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Legends for figures 
Figure 1: Flow chart of the study 
Please note that only 31 out of 34 screened could be studied for nosocomial infection (NI) because 3 
out of the 34 patients did not survive more than 48H. 
NI+: patients that developed care-related infection 
NI-: patients that did not develop care-related infection 
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Figure 2: Admission CGA in trauma patients and follow up over 66 h 
Data are medians +/- [IQ 25; 75] in randomly chosen patients (n = 9) and controls. Note that the time-
dependent changes of CGA never decrease beyond control values during the survey. H corresponds to 
admission time. * p< 0·001 
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Figure 3: Admission CGA values according to the secondary development of nosocomial infection 
(NI+) or its absence (NI-) 
Data are medians +/- IQ [25; 75] in patients with (n=11, NI+) or without (n=20, NI-). * p = 0·003 
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Figure 4: Sequence of vasostatin-I (CGA1-76) and the derived peptides CGA7-40 and CGA47-70 
(UniProtKB, P10645).  
Black arrows indicate where corresponding enzymes cleave CGA47-70 from vasostatin-I. 
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Figure 5: Intracellular translocation of CGA47-70 in vitro into HTP-1 cells. 
Micrographs of THP1 cells incubated with Rho-CGA47-70 (A) or Rho-CGA7-40(B) for 5 min or 15 min. 
THP-1 nuclei were stained with DAPI. Images depicting cellular peptide localization were obtained by 
fluorescence microscopy. Scale bars equal 10µm. 
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Figure 6: CGA47-66 inhibits both nuclear factor-kappa B (NF-kappa B) and Activator protein 1 (AP-1)-
mediated transcription 
The graph shows mean values ± SD of a representative experiment done in triplicate. * p< 0·05. 
Controls correspond to tranfection by luciferase NF-Kappa B or AP-1 before treatment with peptide. 
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Table 1:Demographic, clinical and biological characteristics of the patients on admission 
Data are medians interquartile range [25; 75], or numbers. ∆ SOFA max = maximal change in the 
SOFA from Day 1 during ICU stay. 
Comparisons were assessed between patients with (NI+) or without (NI-) nosocomial infection. 
*p=0·05; **p<0·02; ****p<0·002; *****p<0·001#p<0·04 
Please note that only 31 patients among the 34 screened fulfilled the criteria for NI occurrence (ie: 
survival>48h). CGA values for healthy controls are as follows: 19·5 [2·3; 36·6] ng/ml. 
 
 All (n= 31) NI+ (n = 11/31) NI- (n = 20/31) 
Demography: 
Age (years) 
Gender (M, F) 
Survival (S, NS) 
Length of ICU/hospital 
stay (days) 
 
37·0 [20·75; 60·5]
(25; 9) 
(25; 9) 
8·0 [3·75; 21·25] 
 
 
36·5 [20·75; 
56·25] 
(10; 2) 
(9; 3) 
18·5 [16·0; 27·5] 
 
 
39·0 [20·5; 62·0] 
(15; 7) 
(16; 6) 
4·0 [2·75; 
9·5]***** 
 
Scores: 
Glasgow Coma Score 
Injury Severity Score 
Simplified Acute 
Physiology Score II 
Sequential Organ Failure 
Assessment (SOFA)  
∆ SOFA max 
Multiple Organ 
Dysfunction Score 
Red blood cells 
transfusion (units) 
 
12·5 [3·0; 15] 
27·0 [21·75; 
34·25] 
42·5 [32·25; 
61·75] 
9·0 [5·0; 11·0 
0 [0; 2] 
5 [4; 8·25] 
3·5 [0; 9] 
 
7·5 [3; 15] 
28 [21·75; 37·0] 
43·5 [39·25; 
62·75] 
11·0 [8·25; 13·0] 
1·0 [0; 2·0] 
7·0 [4·25; 10·0] 
4·5 [2·0; 14·75] 
 
13·0 [5·0; 15] 
27·0 [21·5; 30·5] 
41·0 [29·25; 63·5] 
6·0 [3·75; 10·0]** 
0 [0; 2·0] 
5·0 [3·75; 6·5] 
2·5 [0; 6·75] 
Biology: 
Haemoglobin (g/100 ml) 
White blood cells counts 
(Giga/l) 
Chromogranin A (ng/ml) 
Chromogranin A / 
albumin ratio 
C-reactive protein (mg/l) 
Procalcitonin (µg/l) 
Lactate (mmol/l) 
Creatinine (µmol/l) 
 
 
9·9 [8·77; 12·8] 
10·4 [7·42; 12·9] 
78·58 [51·51; 
116·2] 
2·3 [1·38; 3·71] 
21·55 [0; 40] 
0·945 [0.25; 2·06]
2·28 [0·99; 3·20] 
69·5 [59·5; 88·5] 
 
 
9·4 [8·65; 12·78] 
8·65 [5·17; 14·12]
112·3 [88·73; 
144·3] 
3·57 [2·58; 4·69] 
20·3 [2·5; 61·75] 
1·83 [0·52; 5·56] 
2·56 [1·55; 6·13] 
79·5 [63·25; 
93·75] 
 
 
10·3 [8·77; 12·83] 
10·7 [8·77; 12·9] 
64·6 [34·6; 
89·0]**** 
1·775 [1·15; 
2·38]***** 
21·55 [0; 33·75] 
0·59 [0·16; 1·35]* 
1·59 [0·86; 2·93] 
68·0 [50·75; 83·25]
 
Data are medians interquartile range [25; 75], or numbers. ∆ SOFA max = maximal change in the 
SOFA from Day 1 during ICU stay. 
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Comparisons were assessed between patients with (NI+) or without (NI-) nosocomial infection. 
*p=0·05; **p<0·02; ****p<0·002; *****p<0·001, #p<0·04 
Please note that only 31 patients among the 34 screened fulfilled the criteria for NI occurrence (ie: 
survival>48h). CGA values for healthy controls are as follows: 19·5 [2·3; 36·6] ng/ml. 
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Table 2: Demographic and clinical characteristics of the 9 patients included for the time-dependent 
assessment of CGA in vivo 
 
Patients NI  Age (Years) Gender Focus of infection Species involved
Time from admission to 
infection (days) 
1 Y 
 
20 
 
M Lung MR S. aureus 4 
2 Y 20 F Urinary tract P. mirabilis 7 
3 Y 
 
59 
 
F Lung MS S. aureus 4 
4 Y 48 M Lung H. influenza 9 
5 Y 54 M Lung MS S. aureus 4 
6 N 61 M None None 0 
7 N 41 F None None 0 
8 N 44 F None None 0 
9 N 57 M None None 0 
 
NI: nosocomial infection 
M: male; F: female 
MR: Methicillin resistant   
MS: Methicillin sensitive   
Y: yes; N: no 
 
